ImmunityBio, Inc. (NASDAQ:IBRX) surged 10.80% last week, closing at $2.36, ahead of the 37th Piper Sandler Annual Healthcare Conference where it will provide updates on its clinical pipelines. Revenues rose 425% to $32.06 million, driven by strong sales of its bladder cancer treatment, Anktiva, narrowing net loss by 21.6%.

While ImmunityBio (IBRX) shows investment potential, some AI stocks may offer higher returns with less downside risk. For a cheap AI stock benefitting from Trump tariffs, explore the report on the best short-term AI stock. Check out “30 Stocks That Should Double in 3 Years” and “11 Hidden AI Stocks to Buy Right Now” for more insights.

Read more at Yahoo Finance: ImmunityBio (IBRX) Soars 10.8% Ahead of Health Conferences